Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | ZUMA-5: Axi-cel for R/R non-Hodgkin lymphoma

Caron Jacobson • 28 May 2020
EHA 2020
Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T
ZUMA-5

Caron Jacobson, MD, MMSc, of the Dana-Farber Cancer Institute, Boston, MA, discusses the results from ZUMA-5 (NCT03105336), a pivotal, Phase II study investigating the use of axicabtagene ciloleucel in relapsed/refractory follicular lymphoma and marginal cell lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Caron Jacobson

Rapid CAR manufacture
Caron Jacobson et al. • 14 Apr 2023
10:21
Advances in CAR-T therapy for lymphoma
Caron Jacobson et al. • 1 May 2022
2:13
Expanding the reach of CAR-T
Caron Jacobson • 2 Jun 2020
1:52
Impact of immunotherapy on lymphoma
Caron Jacobson • 2 Jun 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals